Lunasin: The Soy Peptide That Blocks Cancer-Related Histone Changes and Survives Digestion
The soy-derived peptide lunasin inhibited histone acetylation (an epigenetic change linked to cancer) in a dose-dependent manner and remained intact and active after oral consumption in rats.
Quick Facts
What This Study Found
Lunasin from various Korean soybean varieties inhibited core histone H3 and H4 acetylation in a dose-dependent manner, with the degree of inhibition correlating to the amount of lunasin present. Both natural soy-derived lunasin and synthetic lunasin showed the same activity.
Critically for practical relevance, lunasin in enriched soy survived in vitro pepsin digestion and was found intact in blood and liver tissue of rats fed lunasin-enriched soy (LES). The extracted lunasin retained its histone acetylation inhibitory activity, demonstrating oral bioavailability — a rare achievement for a dietary peptide of this size.
Key Numbers
How They Did This
Researchers extracted lunasin from multiple Korean soybean varieties and measured its presence by immunostaining. Histone acetylation inhibition was quantified using a non-radioactive histone acetyltransferase assay. Stability was tested through in vitro pepsin digestion. Bioavailability was assessed in rats fed lunasin-enriched soy, with lunasin extracted from blood and liver tissue and tested for intact structure and biological activity.
Why This Research Matters
Most dietary peptides are destroyed during digestion, making them unlikely to have systemic effects. Lunasin is exceptional because it survives stomach acid and reaches the bloodstream intact. Its proposed mechanism — blocking histone acetylation to prevent cancer cell transformation — represents an epigenetic approach to cancer prevention that is fundamentally different from conventional antioxidant-based dietary cancer prevention theories.
The Bigger Picture
Lunasin occupies a unique position in the bioactive peptide field — it's one of the few food-derived peptides with a well-characterized epigenetic mechanism of action. While most food peptides work through enzyme inhibition (like ACE inhibitors from milk), lunasin targets the fundamental machinery of gene expression. This research contributed to the broader understanding that dietary peptides can influence epigenetic processes, and lunasin has since been studied for anti-inflammatory, cholesterol-lowering, and immunomodulatory effects.
What This Study Doesn't Tell Us
This is a preclinical study with in vitro and rat data only — no human evidence exists for lunasin's cancer-preventive effects. The correlation between lunasin content and histone acetylation inhibition doesn't establish that eating soy prevents cancer. The rat bioavailability data doesn't specify what percentage of ingested lunasin reaches the bloodstream intact. The mechanistic model linking histone acetylation inhibition to cancer prevention, while plausible, has not been validated in long-term cancer outcome studies.
Questions This Raises
- ?Is lunasin bioavailable in humans at concentrations sufficient to inhibit histone acetylation in target tissues?
- ?Does regular soy consumption provide enough lunasin for meaningful cancer-preventive effects, or would concentrated supplementation be needed?
Trust & Context
- Key Stat:
- Intact & active after oral feeding Lunasin was found intact in rat blood and liver after oral consumption and still inhibited histone acetylation — rare for a dietary peptide
- Evidence Grade:
- This is a preclinical study combining in vitro histone assays with animal bioavailability data. While it provides strong mechanistic evidence, no human clinical data supports lunasin's cancer-preventive effects. The evidence is promising but early-stage.
- Study Age:
- Published in 2007, this was an early characterization of lunasin's bioavailability and mechanism. Subsequent research has expanded on these findings, though lunasin has not yet progressed to clinical cancer prevention trials.
- Original Title:
- Inhibition of core histone acetylation by the cancer preventive peptide lunasin.
- Published In:
- Journal of agricultural and food chemistry, 55(3), 632-7 (2007)
- Authors:
- Jeong, Hyung Jin(2), Jeong, Jin Boo(2), Kim, Dae Seop(2), de Lumen, Ben O
- Database ID:
- RPEP-01243
Evidence Hierarchy
Frequently Asked Questions
What is histone acetylation and why does blocking it prevent cancer?
Histones are proteins that DNA wraps around, like thread on a spool. Adding chemical groups (acetylation) to histones loosens the DNA wrapping, turning genes on. When tumor suppressor genes are inactivated, abnormal histone acetylation can activate cancer-promoting genes. Lunasin blocks this acetylation, potentially keeping cancer genes turned off during the early stages when cells are being transformed from normal to cancerous.
Can eating soy give you cancer-preventive amounts of lunasin?
This study showed lunasin survives digestion and reaches the bloodstream in rats, which is encouraging. However, the amount of lunasin varies widely between soybean varieties, and it's unknown whether typical soy consumption delivers enough to meaningfully affect histone acetylation in humans. The research supports the concept but doesn't prove dietary soy prevents cancer through this mechanism.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01243APA
Jeong, Hyung Jin; Jeong, Jin Boo; Kim, Dae Seop; de Lumen, Ben O. (2007). Inhibition of core histone acetylation by the cancer preventive peptide lunasin.. Journal of agricultural and food chemistry, 55(3), 632-7.
MLA
Jeong, Hyung Jin, et al. "Inhibition of core histone acetylation by the cancer preventive peptide lunasin.." Journal of agricultural and food chemistry, 2007.
RethinkPeptides
RethinkPeptides Research Database. "Inhibition of core histone acetylation by the cancer prevent..." RPEP-01243. Retrieved from https://rethinkpeptides.com/research/jeong-2007-inhibition-of-core-histone
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.